Last reviewed · How we verify
Triamcinolone + Pirfenidone
Triamcinolone is a corticosteroid that reduces inflammation, while pirfenidone is an antifibrotic that inhibits fibroblast proliferation and collagen synthesis.
Triamcinolone is a corticosteroid that reduces inflammation, while pirfenidone is an antifibrotic that inhibits fibroblast proliferation and collagen synthesis. Used for Idiopathic pulmonary fibrosis.
At a glance
| Generic name | Triamcinolone + Pirfenidone |
|---|---|
| Also known as | Kenalog + KitosCell |
| Sponsor | Centro Dermatológico Dr. Ladislao de la Pascua |
| Drug class | Corticosteroid and antifibrotic |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Triamcinolone works by inhibiting the release of inflammatory mediators, such as histamine and bradykinin, from mast cells and other cells. Pirfenidone, on the other hand, has been shown to inhibit the proliferation of fibroblasts and the synthesis of collagen, which are key components of the extracellular matrix in fibrotic diseases.
Approved indications
- Idiopathic pulmonary fibrosis
Common side effects
- Cough
- Dyspnea
- Fatigue
- Nausea
- Headache
Key clinical trials
- Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |